Why Did Piper Sandler Give Intra-Cellular Therapies Inc (ITCI) Stock Overweight Rating?
Intra-Cellular Therapies Inc (ITCI) stock saw a modest uptick, ending the day at $126.5 which represents a slight increase of $0.30 or 0.24% from the prior close of $126.2. The stock opened at $126.64 and touched a low of $126.
Piper Sandler adjusted its price target on City Holding (NASDAQ:CHCO) shares, bringing it down to $125 from the previous $135 while maintaining a Neutral rating. The $1.75 billion regional bank, ...
In a report released today, Arvind Ramnani from Piper Sandler maintained a Hold rating on PayPal Holdings (PYPL – Research Report), with a ...
Tesla remains the “top buy-and-hold” stock for analysts at Piper Sandler, who massively raised their price target for the ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.59% ...
Piper Sandler raised the firm’s price target on PayPal (PYPL) to $93 from $88 and keeps a Neutral rating on the shares. The firm believes that ...
Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of John Kerins as a ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Piper Sandler analyst Michael Lavery maintained a Buy rating on PepsiCo (PEP – Research Report) today and set a price target of $171.00. The ...
Tesla (TSLA) slips as President Trump considers eliminating EV tax credits and subsidies, while Piper Sandler analysts raise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback